表紙
市場調査レポート

糖尿病薬の調査

Diabetes Drugs Survey

発行 TriMark Publications 商品コード 353580
出版日 ページ情報 英文 220 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
糖尿病薬の調査 Diabetes Drugs Survey
出版日: 2016年01月31日 ページ情報: 英文 220 Pages
概要

糖尿病の蔓延は段階的に増大し、新たな切迫感がもたらされています。

当レポートでは、糖尿病薬について調査分析し、現在使用中の一般的な治療アプローチ、将来的に治療に使用される新興技術なども含め、体系的な情報を提供しています。

第1章 概要

第2章 イントロダクション

  • 糖尿病の人口統計
    • 世界
    • 米国
  • 糖尿病の経済学
    • 世界の糖尿病コスト
    • 米国の糖尿病コスト

第3章 糖尿病について

  • 糖尿病予備軍
  • メタボリックシンドローム
  • 糖尿病と炎症
  • 糖尿病の診断
  • 糖尿病の進行
  • 肥満と糖尿病
  • 2型糖尿病の合併症と併存疾患

第4章 製薬業界と抗糖尿病薬市場

  • 世界の製薬業界
  • 糖尿病治療薬市場全体の市場規模と成長率
  • 糖尿病薬の概要

第5章 非インスリン抗糖尿病薬製品・市場

  • 非インスリン抗糖尿病薬市場の促進要因と動向
  • メグリチニド
  • ビグアニド
  • チアゾリジンジオン
  • αグルコシダーゼ阻害剤
  • アミリンアナログ、など

第6章 インスリン市場

  • インスリン市場の主要企業と市場シェア
  • 特許切れ
  • インスリンバイオシミラー
  • イノベーション戦略
  • インスリン治療の概要
  • 短時間作用型ヒトインスリン市場
  • 即効型インスリンアナログ市場、など

第7章 新興の抗糖尿病技術・製品

  • 抗糖尿病薬市場の予測
  • 人工膵臓
  • インスリン産生細胞
  • 予混合グルカゴン
  • 抗肥満薬
  • インスリン
  • インスリンと抗糖尿病薬の併用

第8章 市場動向、課題、戦略的オプション

  • 概要
  • 糖尿病薬市場の動向
  • 糖尿病市場の課題
  • 戦略的オプション
  • 抗糖尿病薬開発に対するFDAのガイドライン
  • 最近の産業活動

第9章 企業プロファイル

図表

目次
Product Code: TMRDIAS16-01

As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization, as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This report evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes in the future.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. About this Report
  • 1.3. Scope of the Report
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Introduction

  • 2.1. Demographics of Diabetes
    • 2.1.1. Worldwide Diabetes
    • 2.1.2. U.S. Diabetes
  • 2.2. Economics of Diabetes
    • 2.2.1. Worldwide Costs of Diabetes
    • 2.2.2. Costs of Diabetes in the U.S.

3. Understanding Diabetes

  • 3.1. Pre-Diabetes Syndrome
  • 3.2. Metabolic Syndrome
    • 3.2.1. Prevalence of Metabolic Syndrome
    • 3.2.2. Management of Metabolic Syndrome
    • 3.2.3. The Debate Regarding Metabolic Syndrome
  • 3.3. Diabetes and Inflammation
  • 3.4. Diagnosis of Diabetes Mellitus
  • 3.5. Progression of Diabetes
  • 3.6. Obesity and Diabetes
  • 3.7. Complications and Co-Morbidities in Type 2 Diabetes
    • 3.7.1. Preventing Complications and Co-Morbidities in Diabetes

4. Pharmaceutical Industry and the Anti-Diabetes Drug Market

  • 4.1. The Worldwide Pharmaceutical Industry
    • 4.1.1. Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
    • 4.1.2. Global Pharmaceutical Market
  • 4.2. Overall Diabetes Drug Market Size and Growth
    • 4.2.2. Sales Forecast for the Global Anti-diabetes Drug Market
  • 4.3. Diabetic Medications Overview
    • 4.3.1. Recent Trends in Diabetic Drug Usage
    • 4.3.2. Market Influence Factors

5. Non-Insulin Anti-Diabetes Products and Market

  • 5.1. Non-Insulin Anti-Diabetes Drug Market Drivers and Trends
    • 5.1.1. Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
    • 5.1.2. Latest Additions to the U.S. Non-Insulin Diabetes Drug Market
    • 5.1.3. GLP-1 Market Revenue, Market Share, Key Players
    • 5.1.4. DPP-4 Inhibitor Market Revenue, Market Share and Key Players
    • 5.1.5. SGLT-2 Inhibitor Market Revenue, Market Share and Key Players
  • 5.2. Sulfonylureas
  • 5.3. Meglitinides
  • 5.4. Biguanides
  • 5.5. Thiazolidinediones (TZDs)
  • 5.6. α-Glucosidase Inhibitors
  • 5.7. Amylin Analog
  • 5.8. GLP-1 (Glucagon-like Peptide) Analogs and Agonists/Incretin Mimetics
    • 5.8.1. Byetta (Exenatide)
    • 5.8.2. Bydureon (Exenatide LAR)
    • 5.8.3. Victoza (Liraglutide)
    • 5.8.4. Tanzeum (Albiglutide)
    • 5.8.5. Trulicity (Dulaglutide)
  • 5.9. DPP-IV Inhibitors
    • 5.9.1. Januvia (Sitagliptin)
    • 5.9.2. Onglyza (Saxagliptin)
    • 5.9.3. Tradjenta (Linagliptin)
    • 5.9.4. Galvus (Vildagliptin)
    • 5.9.5. Nesina (Alogliptin)
    • 5.9.6. Marizev (Omarigliptin)
  • 5.10. SGLT-2 Inhibitors
    • 5.10.1. Invokana (Canagliflozin)
    • 5.10.2. Farxiga (Dapagliflozin)
    • 5.10.3. Jardiance (Empagliflozin)
    • 5.10.4. Suglat (Ipragliflozin)
    • 5.10.5. Lusefi (Luseogliflozin)
  • 5.11. Fixed Dose Combination Therapies on the Market
  • 5.12. Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
  • 5.13. Comparisons of the Anti-Diabetes Drugs
  • 5.14. Non-Insulin Anti-Diabetes Products in the Pipeline
    • 5.14.1. Novel GLP-1 Agonists and Analogs
    • 5.14.2. Novel DPP-IV Inhibitors
    • 5.14.3. Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
  • 5.15. Emerging Anti-Diabetes Targets and Drugs in the Pipeline
  • 5.16. Novel Approaches to Finding New Drug Targets

6. Insulin Markets

  • 6.1. Major Players and Market Share in the Insulin Market
  • 6.2. Patent Expirations
  • 6.3. Insulin Biosimilars
    • 6.3.1. Regulatory Avenues for Biosimilar Approval
    • 6.3.2. Insulin Biosimilars on the Market
      • 6.3.2.1. Abasaglar (formerly Abasria) and Basaglar
      • 6.3.2.2. Other Biosimilars
      • 6.3.2.3. Key Issues for Insulin Biosimilars
  • 6.4. Innovation Strategies
  • 6.5. Overview of Insulin Therapeutics on the Market
    • 6.5.1. Recommendations for Insulin Initiation and Administration
  • 6.6. Short-Acting Human Insulin Market
  • 6.7. Rapid-Acting Insulin Analog Market
    • 6.7.1. Ultra Fast-Acting Insulins in Development
  • 6.8. Intermediate-Acting Insulin Market
  • 6.9. Long-Acting Insulin Market
    • 6.9.1. Lantus-Sanofi's Insulin Blockbuster
    • 6.9.2. Toujeo-Sanofi's Bid to Maintain Insulin Market Share
    • 6.9.3. Levemir Market
    • 6.9.4. Tresiba Approved for the U.S. Market
    • 6.9.5. Lantus Biosimilars
      • 6.9.5.1. Abasaglar (formerly Abasria) and Basaglar
      • 6.9.5.2. Other Biosimilars
  • 6.10. Insulin Mixtures
  • 6.11. Pipeline Insulins in Development
    • 6.11.1. BIOD-531 (Biodel)
    • 6.11.2. Xultophy (Novo Nordisk)
    • 6.11.3. LixiLan (Sanofi)
    • 6.11.4. rHUPH20 and Insulin (Halozyme)
    • 6.11.5. FIAsp (Novo Nordisk)
    • 6.11.6. BIOD-238, BIOD-250, and BIOD-351 (Biodel)
    • 6.11.7. InsuPatch and InsuPad (Insuline Medical)
    • 6.11.8. MK-1293
    • 6.11.9. Smart Insulins
  • 6.12. Non-Invasive Insulin Delivery
    • 6.12.1. Inhaled Insulin
      • 6.12.1.1. Afrezza
      • 6.12.1.2. Dance Pharmaceuticals and Aerogen (Dance-501)
      • 6.12.1.3. A Chronicle of Inhaled Insulins
    • 6.12.2. Oral Insulin
    • 6.12.3. Transdermal Insulin
  • 6.13. Barriers for Non-Injected Insulin
  • 6.14. Patient Potential for Non-Injected Insulin
  • 6.15. Insulin Delivery Devices
    • 6.15.1. Insulin Pens
    • 6.15.2. Injections Aids
      • 6.15.2.1. Automatic Injectors
      • 6.15.2.2. Syringe Magnifiers
      • 6.15.2.3. Injection Ports
    • 6.15.3. Insulin Jet Injectors
    • 6.15.4. Insulin Pumps
      • 6.15.4.1. External Insulin Pumps
      • 6.15.4.2. Animas OneTouch Ping
      • 6.15.4.3. Animas Vibe
      • 6.15.4.4. Accu-Chek Combo Insulin Pump System (Roche)
      • 6.15.4.5. MiniMed Paradigm Real-Time Revel (Medtronic)
      • 6.15.4.6. MiniMed 530G with Enlite (Medtronic)
      • 6.15.4.7. Insulet Omnipod
      • 6.15.4.8. DANA IIS (Sooil)
      • 6.15.4.9. t:flex (Tandem Diabetes Care)
      • 6.15.4.10. t:slim (Tandem Diabetes Care)
      • 6.15.4.11. Snap (Asante)
    • 6.15.5. Insulin Infusion Sets
    • 6.15.6. Insulin Patch Pumps in Development or Only Available Outside the U.S.
    • 6.15.7. Implantable Insulin Pumps
    • 6.15.8. Insulin Pump Market Share
    • 6.15.9. Drivers of Demand for Pumps
  • 6.16. Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products

  • 7.1. Projections for the Anti-Diabetes Drug Market
  • 7.2. Artificial Pancreas
    • 7.2.1. MiniMed 530G System
    • 7.2.2. Animas Vibe System
    • 7.2.3. Next Generation Medtronic Artificial Pancreas Systems (MiniMed 640G)
    • 7.2.4. FDA's Artificial Pancreas Guidance Document
  • 7.3. Insulin-Producing Cells
    • 7.3.1. Gene Therapy
    • 7.3.2. Cell Therapy Companies for Diabetes
      • 7.3.2.1. ViaCyte (formerly Novocell, Inc.)
      • 7.3.2.2. Sernova
      • 7.3.2.3. Semma Therapeutics
  • 7.4. Pre-Mixed Glucagon for Self-Treating Hypoglycemia
  • 7.5. Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
    • 7.5.1. Xenical (Roche)
    • 7.5.2. Qsymia (Vivus)
    • 7.5.3. Belviq (Arena Pharmaceuticals)
    • 7.5.4. Contrave (Orexigen Therapeutics)
    • 7.5.5. Saxenda
    • 7.5.6. Anti-Obesity Drugs in Development
  • 7.6. Insulin and Anti-Diabetes Drug Combinations
    • 7.6.1. Xultophy (Novo Nordisk)
    • 7.6.2. LixiLan (Sanofi)

8. Market Trends, Challenges and Strategic Options

  • 8.1. Overview
  • 8.2. Diabetes Drug Market Trends
    • 8.2.1. Overview
    • 8.2.2. Emergence of Therapeutics with Improved Administration Characteristics
      • 8.2.2.1. Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
    • 8.2.3. Increasing Prevalence of Obesity
    • 8.2.4. Consumer Preference Drives Product Development in Invasive Technology Segment
  • 8.3. Diabetes Mellitus Market Challenges
    • 8.3.1. Overview
    • 8.3.2. Patent Expirations
    • 8.3.3. Market Prospects of Inhalable Insulin
  • 8.4. Strategic Options
    • 8.4.1. Developing Countries are Key Markets for Growth
    • 8.4.2. Consumer-Driven Marketing Campaigns
    • 8.4.3. Strategies for Successful New Product Launches
    • 8.4.4. Collaborations and Strategic Alliances
  • 8.5. FDA Guidelines for Developing Anti-Diabetic Drugs
  • 8.6. Recent Industry Activity

9. Company Profiles

  • 9.1. A. Menarini
  • 9.2. Abbott Laboratories
  • 9.3. Abbvie
  • 9.4. Amgen
  • 9.5. Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
  • 9.6. Animas (part of Johnson & Johnson)
  • 9.7. Asante
  • 9.8. Astellas Pharma, Inc.
  • 9.9. AstraZeneca PLC
  • 9.10. Bayer
  • 9.11. Becton, Dickinson and Company
  • 9.12. Biocon
  • 9.13. Biodel
  • 9.14. BodyMedia
  • 9.15. Boehringer Ingelheim
  • 9.16. Bristol Myers Squibb
  • 9.17. Cellnovo
  • 9.18. CeQur
  • 9.19. ConjuChem
  • 9.20. Daiichi Sankyo
  • 9.21. Dance Biopharm
  • 9.22. Debiotech
  • 9.23. DexCom
  • 9.24. Echo Therapeutics, Inc.
  • 9.25. Eli Lilly
  • 9.26. FIFTY50. Medical, Inc.
  • 9.27. Flamel Technologies
  • 9.28. Generex Biotechnology Corporation
  • 9.29. GlaxoSmithKline PLC
  • 9.30. Halozyme Therapeutics
  • 9.31. Insulet
  • 9.32. Insuline Medical Ltd.
  • 9.33. Intarcia Therapeutics, Inc.
  • 9.34. Janssen Research & Development
  • 9.35. Johnson & Johnson
  • 9.36. Kowa Pharmaceuticals
  • 9.37. Lexicon Pharmaceuticals
  • 9.38. MannKind Corporation
  • 9.39. Medipacs
  • 9.40. Medtronic
  • 9.41. Merck & Company, Inc.
  • 9.42. Mitsubishi Tanabe Pharma Corporation
  • 9.43. Novartis
  • 9.44. Novo Nordisk
  • 9.45. Oramed Pharmaceuticals
  • 9.46. Orexigen Therapeutics, Inc.
  • 9.47. Owen Mumford
  • 9.48. PhaseBio Pharmaceuticals
  • 9.49. Pfizer
  • 9.50. Prometheon Pharma
  • 9.51. Roche Diagnostics
  • 9.52. Sanofi
  • 9.53. Sernova
  • 9.54. Smiths Medical
  • 9.55. SOOIL Development
  • 9.56. Taisho Pharmaceuticals
  • 9.57. Takeda
  • 9.58. Tandem Diabetes Care, Inc.
  • 9.59. Theracos, Inc.
  • 9.60. Transdermal Specialties, Inc.
  • 9.61. Valeritas
  • 9.62. ViaCyte, Inc. (formerly Novocell)
  • 9.63. Vivus, Inc.
  • 9.64. vTv Therapeutics (formerly TransTech Pharma)
  • 9.65. Ypsomed Holding
  • 9.66. Zealand Pharma

INDEX OF FIGURES

  • Figure 2.1: Worldwide Diabetes Cases, 2015 and 2035
  • Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
  • Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
  • Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
  • Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
  • Figure 2.6: Percentage of U.S. Adults Diagnosed Diabetes by State, 2013
  • Figure 2.7: Number of Deaths from Diabetes by Age in the U.S., 2013
  • Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S., 2013
  • Figure 2.9: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
  • Figure 2.10: How Diabetes Dollars are Spent in the U.S.
  • Figure 3.1: Maintenance of Normal Blood Sugar Levels
  • Figure 3.2: Prevalence of Self-Reported Obesity (BMI 3 30) Among U.S. Adults, 2013
  • Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2012
  • Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 1999-2012
  • Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2012-2019
  • Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2012-2019
  • Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
  • Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Market by Volume, 2014
  • Figure 5.1: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2014
  • Figure 5.2: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2014
  • Figure 5.3: GLP-1 Market Share by Brand, 2014
  • Figure 5.4: GLP-1 Market Share of Key Players, 2014
  • Figure 5.5: DPP-4 Inhibitor Market Share by Brand, 2014
  • Figure 5.6: DPP-4 Inhibitor Market Share of Key Players, 2014
  • Figure 5.7: Overview of GLP-1 and Blood Glucose
  • Figure 5.8: Overview of DPP-4 Inhibitors and Blood Glucose
  • Figure 5.9: SGLT-2 Inhibitor Mechanism of Action
  • Figure 6.1: Worldwide Insulin Market Share (Value), 2014
  • Figure 6.2: U.S. Insulin Market Share (Value), 2014
  • Figure 6.3: Short-Acting Human Insulin Worldwide Market Share by Company, 2014
  • Figure 6.4: Rapid-Acting Insulin Worldwide Market Share by Company, 2014
  • Figure 6.5: Intermediate-Acting Human Insulin Worldwide Market Share by Company, 2014
  • Figure 6.6: Long-Acting Insulin Worldwide Market Share by Company, 2014
  • Figure 6.7: Market Share of Basal Insulins in Emerging Markets, 2014
  • Figure 6.8: Global Sales of Lantus, 2005-2014
  • Figure 6.9: Global Sales of Levemir, 2011-2014
  • Figure 6.10: Insulin Pump Market Share, 2014

INDEX OF TABLES

  • Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2015 and 2035
  • Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group), 2015 and 2035
  • Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
  • Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
  • Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
  • Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
  • Table 2.7: Cost of Diagnosed Diabetes in the U.S.
  • Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes
  • Table 2.9: Healthcare Utilization by Diabetic Patients
  • Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic Syndrome Criteria
  • Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.4: Additional Metabolic Criteria for Research
  • Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 3.6: Prevalence of Complications Among Patients with Diabetes
  • Table 3.7: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 3.9: Major Causes of End-Stage Renal Disease
  • Table 3.10: Clinical Recommendations for Adults with Diabetes
  • Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
  • Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2014
  • Table 4.3: Leading Therapy Classes for R&D, 2014
  • Table 4.4: Leading Disease Indications for R&D, 2014
  • Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
  • Table 4.6: Global Pharmaceutical Sales by Region and Country, 2013 and 2018 (estimated) and CAGR 2009-2013 and 2014-2018 (estimated)
  • Table 4.7: World Pharmaceutical Sales Share by Region, 2013
  • Table 4.8: Leading Ten Therapeutic Classes by Global Sales, 2010-2014
  • Table 4.9: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2018
  • Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2018
  • Table 4.11: Leading Therapeutic Classes by U.S. Sales, 2010-2014
  • Table 4.12: Top Selling Drugs Worldwide by Sales, 2014
  • Table 4.13: Top Selling Drugs in the U.S. by Sales, 2014
  • Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2014
  • Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.17: Anti-Diabetic Therapy Markets, 2014
  • Table 4.18: Top Ten Branded Anti-Diabetics by Sales Worldwide, 2014
  • Table 4.19: Top Ten Branded Anti-Diabetics by Monthly Prescriptions Worldwide, 2014
  • Table 4.20: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
  • Table 4.21: Summary of Glucose-Lowering Interventions as Monotherapy
  • Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
  • Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
  • Table 5.3: Relative Efficacy of Diabetes Drugs
  • Table 5.4: Worldwide Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.5: U.S. Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.6: Diabetes Drugs Approved for U.S. Market, 2014 and 2015
  • Table 5.7: GLP-1 Drug Revenues in 2014
  • Table 5.8: DPP-4 Inhibitor Revenues in 2014
  • Table 5.9: SGLT-2 Inhibitor Revenues in 2014
  • Table 5.10: Fixed-Dose Oral Anti-Diabetes Drug Combinations
  • Table 5.11: GLP-1 Agonist Pipeline: Selected Drugs in Development
  • Table 5.12: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.13: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.14: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
  • Table 5.15: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2014
  • Table 6.2: Worldwide Insulin Market, 2012-2019
  • Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2014
  • Table 6.4: U.S. Insulin Market, 2012-2019
  • Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2014
  • Table 6.6: Worldwide Insulin Market by Type (% Market Value), 2014
  • Table 6.7: Worldwide Insulin Sales and Value Market Share by Company, 2014
  • Table 6.8: U.S. Insulin Sales and Value Market Share by Company, 2014
  • Table 6.9: Insulins on the U.S. Market
  • Table 6.10: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
  • Table 6.11: Comparison of Recommendations from Existing Guidelines
  • Table 6.12: Pharmacokinetics of Short-Acting Human Insulins
  • Table 6.13: Short-Acting Human Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.14: Pharmacokinetics of Rapid-Acting Insulins
  • Table 6.15: Rapid-Acting Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.16: Pharmacokinetics of Intermediate-Acting Insulins
  • Table 6.17: Intermediate-Acting Human Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.18: Pharmacokinetics of Long-Acting Insulins
  • Table 6.19: Long-Acting Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.20: Pharmacokinetics of Insulin Mixtures
  • Table 6.21: A Comparison of Existing Insulin Delivery Devices
  • Table 6.22: Insulin Pens
  • Table 6.23: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
  • Table 6.24: Injection Aids
  • Table 6.25: Jet Injectors
  • Table 6.26: Control Averages by Treatment
  • Table 6.27: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
  • Table 6.28: Leading Insulin Pump Manufacturers
  • Table 6.29: Comparison of Current External Insulin Pumps on the Market
  • Table 6.30: Insulin Infusion Sets
  • Table 6.31: Worldwide Insulin Pump Market, 2013-2019
  • Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
  • Table 7.2: Cells of the Pancreas
  • Table 8.1: BRIC Countries, Percentage of GDP Spent on Healthcare, 2013
Back to Top